Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
|Articles|April 1, 2020
Answers to angle closures quiz
Advertisement
1. c. Although the risk of progression was reduced by 50% with LPI, less than 5% of subjects in both groups progressed.
2. d. Both (a) and (c).
3. d. All of the above
4. a. True.
5. d. Both (a) and (c)
6. a. Male sex.
7. b. False.
Advertisement
Related to this article
Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."
Michael Cymbor, OD, FAAO, gives an overview of a rapid fire lecture he gave in collaboration with Andrew Rixon OD, FAAO; Austin Lifferth, OD, FAAO; and Derek MacDonald, OD, FAAO, at AAOpt 2026.
Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.
Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.
Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: Aflibercept 8 mg extends RVO dosing as Amsler misses AMD damage
3
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
4
The patient who could not scroll: When prism became the practical solution
5